Skip to main content
. Author manuscript; available in PMC: 2016 Jun 2.
Published in final edited form as: Annu Rev Biochem. 2015 Jan 26;84:739–764. doi: 10.1146/annurev-biochem-060614-034402

Figure 3. Therapeutic antibodies target EGFR and Her2 in versatile ways.

Figure 3

Structure of the EGFR-Cetuximab (PDB ID 1YY9), Her2-Pertuzumab (PDB ID 1S78), and Her2-Trastuzumab (PDB ID 1N8Z) complexes.